JP4080541B2
(ja)
*
|
1996-10-18 |
2008-04-23 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
|
AU1324300A
(en)
*
|
1998-10-26 |
2000-05-15 |
Vertex Pharmaceuticals Incorporated |
Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
AU2001251165A1
(en)
*
|
2000-04-03 |
2001-10-15 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
US6613801B2
(en)
*
|
2000-05-30 |
2003-09-02 |
Transtech Pharma, Inc. |
Method for the synthesis of compounds of formula I and their uses thereof
|
AR034127A1
(es)
*
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
US6727366B2
(en)
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
WO2002057287A2
(en)
|
2001-01-22 |
2002-07-25 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
CN1494425B
(zh)
|
2001-03-05 |
2011-12-07 |
特兰斯泰克制药公司 |
用作治疗剂的羧酰胺衍生物
|
JP2004523565A
(ja)
|
2001-03-05 |
2004-08-05 |
トランス テック ファーマ,インコーポレイテッド |
治療因子としてのベンゾイミダゾール誘導体
|
ATE349463T1
(de)
|
2001-07-11 |
2007-01-15 |
Vertex Pharma |
Verbrückte bizyklische serinproteaseinhibitoren
|
NZ531681A
(en)
*
|
2001-10-24 |
2007-05-31 |
Vertex Pharma |
Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CN101597262A
(zh)
|
2002-03-05 |
2009-12-09 |
特兰斯泰克制药公司 |
抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
|
NZ561851A
(en)
|
2002-04-11 |
2009-05-31 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
|
ES2315568T3
(es)
|
2002-05-20 |
2009-04-01 |
Bristol-Myers Squibb Company |
Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
|
EP1506172B1
(en)
|
2002-05-20 |
2011-03-30 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
ATE481106T1
(de)
|
2002-05-20 |
2010-10-15 |
Bristol Myers Squibb Co |
Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
CA2521678A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
TW200510391A
(en)
*
|
2003-04-11 |
2005-03-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
PT1615613E
(pt)
*
|
2003-04-18 |
2010-02-09 |
Enanta Pharm Inc |
Inibidores da serina protease da hepatite c macrocíclicos de quinoxalinilo
|
PT1654261E
(pt)
|
2003-05-21 |
2008-01-18 |
Boehringer Ingelheim Int |
Compostos inibidores da hepatite c
|
EP1646642A2
(en)
*
|
2003-07-18 |
2006-04-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
TW201127828A
(en)
|
2003-09-05 |
2011-08-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
EP1664091A1
(en)
*
|
2003-09-18 |
2006-06-07 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
DE602004031645D1
(de)
|
2003-09-22 |
2011-04-14 |
Boehringer Ingelheim Pharma |
Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
|
CA2541634A1
(en)
*
|
2003-10-10 |
2005-04-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
DK1680137T3
(da)
|
2003-10-14 |
2013-02-18 |
Hoffmann La Roche |
Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
KR20060120166A
(ko)
|
2003-10-27 |
2006-11-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv ns3-ns4a 단백질분해효소 저항성 돌연변이
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2549851C
(en)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis c virus
|
AU2005212257A1
(en)
*
|
2004-02-04 |
2005-08-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
PT1719773E
(pt)
|
2004-02-24 |
2009-06-03 |
Japan Tobacco Inc |
Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
|
AU2005254057B2
(en)
|
2004-06-15 |
2011-02-17 |
Isis Pharmaceuticals, Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
US20070265222A1
(en)
|
2004-06-24 |
2007-11-15 |
Maccoss Malcolm |
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
EP1771454B1
(en)
|
2004-07-20 |
2011-06-15 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibitor peptide analogs
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
CN102160891A
(zh)
|
2004-10-01 |
2011-08-24 |
威特克斯医药股份有限公司 |
Hcv ns3-ns4a蛋白酶抑制
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7879797B2
(en)
|
2005-05-02 |
2011-02-01 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
TWI387603B
(zh)
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Hcv ns3蛋白酶抑制劑
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
KR20080036598A
(ko)
|
2005-08-01 |
2008-04-28 |
머크 앤드 캄파니 인코포레이티드 |
Hcv ns3 프로테아제 억제제로서의 마크로사이클릭펩티드
|
AU2006275413B2
(en)
|
2005-08-02 |
2012-07-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
EP1915054A4
(en)
|
2005-08-09 |
2010-09-01 |
Merck Sharp & Dohme |
CYCLIC ACETAL DERIVATIVES OF RIBONUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
|
EP2357170A1
(en)
|
2005-08-19 |
2011-08-17 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
EP1951748B1
(en)
|
2005-11-11 |
2013-07-24 |
Vertex Pharmaceuticals, Inc. |
Hepatitis c virus variants
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
JP5436864B2
(ja)
|
2006-02-27 |
2014-03-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vx−950を含む共結晶体およびそれを含む医薬組成物
|
EP1993994A2
(en)
|
2006-03-16 |
2008-11-26 |
Vertex Pharmceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
CA2648298A1
(en)
*
|
2006-04-11 |
2007-10-25 |
Novartis Ag |
Organic compounds and their uses
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
US8268776B2
(en)
|
2006-06-06 |
2012-09-18 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
US9526769B2
(en)
|
2006-06-06 |
2016-12-27 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
WO2008063727A2
(en)
*
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
WO2008027397A2
(en)
*
|
2006-08-28 |
2008-03-06 |
Vertex Pharmaceuticals Incorporated |
Method for identifying protease inhibitors
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
WO2008051514A2
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
US8138164B2
(en)
|
2006-10-24 |
2012-03-20 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
CN101568346B
(zh)
|
2006-10-27 |
2015-11-25 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
CA2667031C
(en)
|
2006-10-27 |
2013-01-22 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2007335962B2
(en)
|
2006-12-20 |
2012-09-06 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Antiviral indoles
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
AU2008213147A1
(en)
*
|
2007-02-06 |
2008-08-14 |
Chelsea Therapeutics, Inc. |
New compounds, methods for their preparation and use thereof
|
NZ579295A
(en)
|
2007-02-27 |
2012-03-30 |
Vertex Pharma |
Inhibitors of serine proteases
|
ES2379905T3
(es)
|
2007-02-27 |
2012-05-04 |
Vertex Pharmceuticals Incorporated |
Co-cristales y composiciones farmacéuticas que los comprenden
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
US7964580B2
(en)
*
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CN102872461A
(zh)
|
2007-05-04 |
2013-01-16 |
弗特克斯药品有限公司 |
用于治疗hcv感染的组合治疗
|
EP2162431B1
(en)
|
2007-06-29 |
2017-06-07 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US8513186B2
(en)
|
2007-06-29 |
2013-08-20 |
Gilead Sciences, Inc. |
Antiviral compounds
|
EP2178885A1
(en)
|
2007-07-17 |
2010-04-28 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic indole derivatives for the treatment of hepatitis c infections
|
WO2009010804A1
(en)
|
2007-07-19 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic compounds as antiviral agents
|
CL2008002549A1
(es)
*
|
2007-08-30 |
2010-09-03 |
Vertex Pharma |
Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
US8383583B2
(en)
|
2007-10-26 |
2013-02-26 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
|
CA2708047A1
(en)
|
2007-12-06 |
2009-06-11 |
Enanta Pharmaceuticals, Inc. |
Process for making macrocyclic oximyl hepatitis c protease inhibitors
|
CN102015652A
(zh)
|
2008-03-20 |
2011-04-13 |
益安药业 |
作为丙型肝炎病毒抑制剂的氟化大环化合物
|
CA2720850A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
PL2310095T3
(pl)
|
2008-07-22 |
2013-03-29 |
Msd Italia Srl |
Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
EP3025727A1
(en)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Methods of treating liver disease
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
EP2408449A4
(en)
|
2009-03-18 |
2012-08-08 |
Univ Leland Stanford Junior |
METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
|
WO2011014487A1
(en)
|
2009-07-30 |
2011-02-03 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
US8389560B2
(en)
|
2009-09-15 |
2013-03-05 |
Taigen Biotechnology Co., Ltd. |
HCV protease inhibitors
|
TWI517850B
(zh)
|
2009-09-30 |
2016-01-21 |
Vtv治療有限責任公司 |
經取代之咪唑衍生物及其使用方法
|
AU2011209051B2
(en)
|
2010-01-27 |
2015-01-15 |
AB Pharma Ltd. |
Polyheterocyclic compounds highly potent as HCV inhibitors
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012171332A1
(zh)
|
2011-06-16 |
2012-12-20 |
爱博新药研发(上海)有限公司 |
抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
|
WO2013072328A1
(en)
|
2011-11-14 |
2013-05-23 |
Sanofi |
Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
EP2780026B1
(en)
|
2011-11-15 |
2019-10-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
MX349036B
(es)
|
2011-12-06 |
2017-07-07 |
Univ Leland Stanford Junior |
Metodos y composiciones para tratar enfermedades virales.
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
WO2014053533A1
(en)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
EP2899207A1
(en)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
New method for testing HCV protease inhibition
|
JP2017512183A
(ja)
|
2014-02-13 |
2017-05-18 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
プロドラッグ化合物およびそれらの使用
|
CN106687118A
(zh)
|
2014-07-02 |
2017-05-17 |
配体药物公司 |
前药化合物及其用途
|
US11970482B2
(en)
|
2018-01-09 |
2024-04-30 |
Ligand Pharmaceuticals Inc. |
Acetal compounds and therapeutic uses thereof
|
JP2022510407A
(ja)
|
2018-12-04 |
2022-01-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
|
CN114516810B
(zh)
*
|
2022-01-18 |
2023-12-26 |
浙江奥翔药业股份有限公司 |
制备药物中间体2-氨基-4-羟基苯甲酸的方法
|